MNPR | tickerfilter.com

Fundamental analysis

22%

Profitability 0%

Dept financing 6%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-16.48%

1 Month

3.36%

3 Months

18.11%

6 Months

441.01%

1 Year

4,706.99%

2 Year

2,139.53%

Key data

Stock price

$28.89

P/E Ratio

0.00

DAY RANGE

$26.64 - $29.51

EPS

-$0.70

52 WEEK RANGE

$0.34 - $54.30

52 WEEK CHANGE

$4,791.64

MARKET CAP

23.727 M

YIELD

N/A

SHARES OUTSTANDING

17.602 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.03

PUBLIC FLOAT

AVERAGE 10 VOLUME

$38,071

AVERAGE 30 VOLUME

$32,093

Company detail

CEO: Chandler D. Robinson
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

MNPR - Monopar Therapeutics